ISLE

15-12G - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

25-NSE - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

ST. PETERSBURG, Fla., Aug. 25, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corp. (the "Company") (NASDAQ:ISLE, ISLEW))) today announced that it has cancelled its special meeting of shareholders that was previously scheduled for August 26, 2022, and that it will redeem all of its outstanding ordinary shares that were included in the units issued in its initial public offering (the "public shares"), effective as of the close of business on August 29, 2022, as the Company will not consummate an initial business combination on or prior to September 1, 2022. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combinati

10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

DEF 14A - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

PRE 14A - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

ST. PETERSBURG, Fla., June 30, 2022 /PRNewswire/ -- Isleworth Healthcare Acquisition Corporation (NASDAQ:ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agreement is effective immediately, and contains mutual releases and covenants not to sue. A copy of the Termination Agreement is filed as an exhibit to

-Reuters

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites. For details on in-person poster presentations, please see the

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

8-K - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)

AVENTURA, Fla. and NATICK, Mass., May 18, 2022 /PRNewswire/ -- Cytovia Therapeutics,  LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online.  The abstract was released on May 12, 2022. The e-poster present

NT 10-Q - Isleworth Healthcare Acquisition Corp. (0001837997) (Filer)

425 - Isleworth Healthcare Acquisition Corp. (0001837997) (Subject)